The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world comparison of low- versus high-dose continuous 5FU infusion in patients receiving triplet chemotherapy plus bevacizumab for newly diagnosed metastatic colorectal cancer (mCRC).
 
William Joseph Chapin
No Relationships to Disclose
 
Wei-Ting Hwang
Employment - Janssen (I)
Research Funding - Novartis
 
Ronac Mamtani
Honoraria - Flatiron Health
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Genentech/Roche; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Merck
 
Mark H. O'Hara
Consulting or Advisory Role - Alligator Bioscience; Geneos; Natera; Ono Pharmaceutical; PsiOxus Therapeutics; Strike Bio
Research Funding - Arcus Biosciences (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genmab (Inst); HiberCell (Inst); Lilly (Inst); Natera (Inst); Parker Institute for Cancer Immunotherapy (Inst); PsiOxus Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune